Cortical dysplasia is a condition that affects how the brain develops before birth, causing groups of brain cells to form incorrectly in the outermost layer of the brain. This malformation is one of the most common reasons why some people, especially children, develop seizures that don’t respond well to standard epilepsy medications. While the condition itself cannot be reversed, understanding the available treatment options—from medications and dietary approaches to surgical interventions and emerging therapies being tested in research—can help families and patients navigate their care journey with greater confidence and hope.

Understanding Treatment Goals for Cortical Dysplasia

When someone receives a diagnosis of cortical dysplasia, the primary focus of treatment is controlling seizures and improving quality of life. The condition occurs when neurons—the specialized cells that send electrical signals throughout the brain—do not migrate and organize properly during development in the womb. This leads to areas of the brain where cells are arranged abnormally, which can trigger abnormal electrical activity and cause epilepsy, a condition characterized by repeated seizures.^[1]

Treatment approaches vary significantly depending on several factors. The type of cortical dysplasia matters greatly. Type I is often harder to detect on brain scans and may not cause seizures until adulthood, while Type II is more severe, typically appears in children, and is more easily visible on imaging tests. Type III combines features of the other types along with additional brain abnormalities such as tumors or scar tissue. The location of the abnormal tissue in the brain, the age when seizures first begin, and how well seizures respond to initial treatments all influence the treatment plan.^[2]

Medical societies and epilepsy specialists have established treatment guidelines that typically follow a stepped approach. Doctors start with medication management as the first line of defense. However, cortical dysplasia is known as one of the forms of epilepsy that responds poorly to conventional anti-seizure medications. Research shows that approximately 80% of people with focal cortical dysplasia find that medications alone do not permanently control their seizures, compared to about one-third of people with other forms of epilepsy. This resistance to medication is why alternative treatments, particularly surgery, play such a crucial role in managing this condition.^[4]

Beyond controlling seizures, treatment aims to address related symptoms. Some individuals with cortical dysplasia experience learning difficulties, problems with concentration, or developmental delays. Children may need educational support and therapy services. Physical therapy might be necessary for those who develop muscle weakness on one side of the body, a condition called hemiparesis. The goal is not just to stop seizures but to help patients live as fully and independently as possible.^[1]

Standard Medical Treatment

The first step in treating cortical dysplasia almost always involves antiepileptic drugs, also called anti-seizure medications or anticonvulsants. Doctors prescribe these medications to help reduce the abnormal electrical activity in the brain that triggers seizures. While no specific medication has been proven to work better than others specifically for cortical dysplasia, neurologists typically try several different drugs to find the most effective combination with the fewest side effects.^[2]

The challenge with medication treatment for cortical dysplasia is that it often provides incomplete control. The abnormal brain tissue at the root of the condition continuously generates abnormal electrical signals, and standard medications may not adequately suppress this activity. However, even when medications don’t completely eliminate seizures, they may reduce their frequency or severity, which can significantly improve daily functioning and safety.^[9]

Treatment duration with anti-seizure medications varies greatly. Some patients may need to take medication for many years or even for life, particularly if surgery is not an option or if they continue to have occasional breakthrough seizures. Doctors typically start with one medication and gradually increase the dose while monitoring for effectiveness and side effects. If the first medication doesn’t work adequately, they may add a second drug or switch to a different one entirely. This process can take months as doctors carefully adjust dosages and combinations.^[2]

Common side effects of antiepileptic drugs can include drowsiness, dizziness, coordination problems, and cognitive effects such as difficulty concentrating or slower thinking. Some medications cause weight gain or loss, mood changes, or skin reactions. Children may experience behavioral changes or learning difficulties. Because side effects vary widely depending on the specific medication and the individual patient, close monitoring by healthcare providers is essential. Parents and patients should report any concerning symptoms so doctors can adjust treatment as needed.^[2]

Beyond pharmaceuticals, a specialized eating plan called the ketogenic diet has emerged as an important non-surgical treatment option for cortical dysplasia, particularly in children. This high-fat, very low-carbohydrate diet changes how the body produces energy, forcing it to burn fat instead of sugar. Scientists believe this metabolic shift may reduce seizure activity through several mechanisms, including changes in brain chemistry and reduction of inflammation.^[2]

The ketogenic diet requires careful medical supervision because it is not simply a matter of cutting carbohydrates. The diet must be precisely calculated and balanced to ensure proper nutrition while maintaining the metabolic state needed for seizure control. A registered dietitian experienced in ketogenic therapy works with families to create meal plans, and regular monitoring of blood and urine is necessary to ensure the diet is working properly and not causing harmful side effects. Research suggests the ketogenic diet can help control seizures in children with various forms of epilepsy, though its effectiveness specifically for cortical dysplasia is still being studied.^[9]

Surgical Treatment Options

When medications fail to control seizures—a situation known as drug-resistant epilepsy or refractory epilepsy—surgery becomes an important consideration. For cortical dysplasia, surgical removal of the abnormal brain tissue offers the best chance of becoming seizure-free. In fact, cortical dysplasia is the most common reason children undergo epilepsy surgery, and it is a frequent indication for surgery in adults as well.^[5]

The goal of surgery is to remove or disconnect the area of abnormal brain tissue that is generating seizures while preserving healthy brain function. Studies have shown remarkably positive outcomes: up to 67% of patients who undergo surgery for focal cortical dysplasia achieve complete freedom from seizures. This success rate makes surgery a potentially life-changing option for people whose seizures don’t respond to medication.^[4]

Several types of surgical procedures may be considered depending on the location and extent of the cortical dysplasia. A lesionectomy involves removing the specific abnormal area of brain tissue visible on imaging scans. For more extensive dysplasia affecting a larger region, surgeons may perform a larger resection to remove all the affected tissue. In severe cases where dysplasia affects an entire half of the brain and causes devastating seizures, a hemispherectomy—removing or disconnecting an entire cerebral hemisphere—may be necessary. Another technique called multiple subpial transections involves making small cuts in the brain to interrupt abnormal electrical pathways without removing tissue, used when the dysplasia is located in areas of the brain that control vital functions like speech or movement.^[7]

The decision to proceed with surgery requires extensive evaluation. Not everyone with cortical dysplasia is a good surgical candidate. Doctors must be able to clearly identify where the seizures are starting and confirm that the abnormal tissue can be safely removed without causing unacceptable neurological deficits. This evaluation typically involves multiple specialized tests beyond standard brain MRI scans. These may include prolonged video EEG monitoring to record seizures and pinpoint their origin, PET scans that show areas of abnormal metabolism in the brain, and sometimes placement of electrodes directly on or in the brain to map seizure activity with precision.^[5]

One significant challenge with cortical dysplasia is that the abnormal tissue visible on an MRI scan may be smaller than the actual seizure-generating region. Sometimes the dysplasia is so subtle that it doesn’t show up on MRI at all, even with the most advanced imaging techniques. This is particularly true for Type I cortical dysplasia. Advanced imaging centers have developed specialized protocols, including fusion of high-resolution MRI with PET scans, to better detect these subtle lesions and define their extent. This detailed mapping is crucial because incomplete removal of the abnormal tissue is a major reason why some patients continue having seizures after surgery.^[5]

Surgical risks include those common to any brain operation: infection, bleeding, and adverse reactions to anesthesia. More specific to epilepsy surgery are risks of new neurological problems such as weakness, vision changes, or language difficulties, depending on which part of the brain is operated on. The younger the patient, particularly infants and young children, the better the brain’s ability to reorganize and compensate for removed tissue. However, surgery still carries the risk of decreased motor function or other deficits. These risks must be carefully weighed against the consequences of ongoing, uncontrolled seizures, which include injury from falls, cognitive decline, social isolation, and the risk of sudden unexpected death in epilepsy (SUDEP).^[2]

Neurostimulation Devices

For patients who are not good candidates for surgery—either because the dysplasia is in a critical area of the brain that cannot be safely removed, because the abnormal tissue is too widespread, or because surgery has been tried but seizures persist—implantable devices that deliver electrical stimulation offer another treatment avenue. These technologies don’t cure the condition but can significantly reduce seizure frequency and severity.^[2]

The vagus nerve stimulator (VNS) is the most established device therapy for drug-resistant epilepsy, including that caused by cortical dysplasia. This small device is surgically implanted under the skin of the chest, similar to a pacemaker, with a wire that connects to the vagus nerve in the neck. The device delivers regular, mild electrical pulses to the vagus nerve, which carries signals to areas of the brain involved in seizure control. Research has shown that for widespread cortical dysplasias that cannot be surgically removed, VNS can produce response rates greater than 50%, meaning more than half of patients experience a significant reduction in seizure frequency. While most patients don’t become completely seizure-free with VNS, even a 50% reduction in seizures can dramatically improve quality of life.^[9]

The procedure to implant a VNS device is relatively minor compared to brain surgery. Risks include infection at the surgical site and continued seizures, though usually at a reduced frequency. Some patients experience side effects such as hoarseness, cough, or throat discomfort when the device is stimulating, though these effects often diminish over time as the body adjusts. The device settings can be adjusted non-invasively after implantation to optimize seizure control while minimizing side effects.^[2]

Not receiving treatment with a VNS when it’s recommended as an option carries its own risks. Ongoing, uncontrolled seizures can lead to worsening of the epilepsy over time, loss of developmental skills in children, injuries from seizure-related falls or accidents, and significantly reduced quality of life. The cumulative burden of frequent seizures takes a toll on cognitive function, mental health, and the ability to participate in normal life activities.^[2]

Treatment Being Tested in Clinical Trials

Exciting advances in understanding the genetic causes of cortical dysplasia have opened new doors for potential treatments that target the root biological problems rather than just managing symptoms. These experimental approaches are being studied in clinical trials and represent hope for better treatment options in the future.

Recent groundbreaking research has identified genetic mutations that occur only in brain tissue—not in blood or other parts of the body—in a significant number of people with cortical dysplasia Type II. Scientists have discovered mutations in genes called TSC1, TSC2, and MTOR in the abnormal brain tissue of patients with this condition. These genes are all part of a biological pathway called the mTOR pathway, which controls how cells grow, divide, and function, particularly in the developing brain.^[14]

When these genes are mutated, they cause excessive activity of the mTOR pathway. This overactivity leads to the formation of abnormally large cells and disorganized brain tissue characteristic of cortical dysplasia. Understanding this mechanism has led researchers to investigate whether drugs that inhibit the mTOR pathway might treat the condition. These drugs, called mTOR inhibitors, include medications like rapamycin (also called sirolimus) and everolimus, which were originally developed to prevent organ rejection after transplants and to treat certain cancers.^[14]

Studies in laboratory animals have provided crucial evidence that mTOR inhibitors might work for cortical dysplasia. Researchers have successfully created mice with brain-only mutations in the TSC1 and TSC2 genes, producing animals that develop brain abnormalities similar to human cortical dysplasia. When these mice are treated with mTOR inhibitors, the abnormal growth of brain cells is reduced and seizures are decreased. This animal research provides the scientific foundation for testing these drugs in humans.^[14]

Currently, everolimus is undergoing Phase II clinical trials specifically for the treatment of focal cortical dysplasia. Phase II trials are designed to evaluate whether a drug is effective for a particular condition and to further assess its safety profile. In these trials, patients with cortical dysplasia who have drug-resistant seizures receive everolimus, and researchers carefully monitor both seizure frequency and any side effects. The goal is to determine whether blocking the overactive mTOR pathway in the brain can reduce seizure activity without causing unacceptable side effects.^[14]

The mechanism of action of mTOR inhibitors is fundamentally different from traditional anti-seizure medications. Rather than simply dampening electrical activity in the brain, these drugs target the molecular abnormality that causes the brain cells to develop incorrectly in the first place. By inhibiting the mTOR pathway, these medications may be able to normalize some of the cellular abnormalities, reduce the production of abnormal electrical signals, and potentially modify the disease process itself.^[9]

Preliminary results from studies using mTOR inhibitors in related conditions have been encouraging. In patients with tuberous sclerosis—a genetic disorder that also involves mTOR pathway mutations and causes brain lesions similar to cortical dysplasia—everolimus has shown effectiveness in reducing seizures. This provides hope that similar benefits might be seen in focal cortical dysplasia. However, researchers emphasize that more data from ongoing clinical trials are needed before mTOR inhibitors can be considered a standard treatment.^[9]

These clinical trials represent a shift toward precision medicine in epilepsy treatment. By identifying the specific genetic mutations present in a patient’s brain tissue (which requires obtaining tissue through biopsy or surgery), doctors may eventually be able to select treatments targeted to each individual’s underlying molecular abnormality. This approach could be particularly valuable for the approximately 30% of cortical dysplasia Type II patients who have been found to have brain-only mutations in the mTOR pathway genes.^[14]

Clinical trials for cortical dysplasia treatments are being conducted at specialized epilepsy centers, primarily in the United States and Europe. Eligibility for these trials typically requires confirmed diagnosis of focal cortical dysplasia, evidence of drug-resistant seizures, and detailed characterization of the genetic mutations present. Patients interested in participating in clinical trials should discuss this option with their neurologist, who can provide information about available studies and help determine if enrollment would be appropriate.^[14]

Beyond mTOR inhibitors, researchers are exploring other innovative approaches to treating cortical dysplasia. Advanced imaging techniques are being developed to better detect subtle dysplasias that are currently invisible on standard MRI scans. Improved detection could lead to more patients being identified as surgical candidates. Scientists are also investigating whether other molecular pathways besides mTOR play a role in cortical dysplasia, which could reveal additional drug targets. The field of epilepsy genetics is rapidly evolving, and ongoing discoveries continue to provide new insights into potential therapeutic strategies.^[15]

Most Common Treatment Methods

• Antiepileptic Medications
  • First-line treatment approach using various anti-seizure drugs to reduce abnormal electrical activity in the brain
  • Multiple medications may be tried to find the most effective combination with acceptable side effects
  • Treatment may continue for years or throughout life depending on seizure control
  • Approximately 80% of patients with focal cortical dysplasia continue having seizures despite medication trials
• Ketogenic Diet
  • Specialized high-fat, very low-carbohydrate eating plan particularly used in children
  • Changes brain metabolism by forcing the body to burn fat instead of glucose for energy
  • Requires precise calculation and medical supervision by experienced dietitians
  • May modify disease progression by affecting brain chemistry and reducing inflammation
• Surgical Resection
  • Removal of abnormal brain tissue generating seizures when medications fail to control symptoms
  • Up to 67% of patients achieve complete seizure freedom after successful surgery
  • Different surgical approaches include lesionectomy, larger resections, hemispherectomy, or multiple subpial transections
  • Most common reason for epilepsy surgery in children with drug-resistant seizures
  • Requires extensive pre-surgical evaluation using advanced imaging and monitoring techniques
• Vagus Nerve Stimulation (VNS)
  • Implantable device that delivers electrical pulses to the vagus nerve to reduce seizure frequency
  • Option when brain surgery is not possible or has not been successful
  • Produces response rates greater than 50% in patients with widespread dysplasias
  • Device settings can be adjusted after implantation to optimize seizure control
• mTOR Inhibitor Therapy (Experimental)
  • Medications like everolimus currently in Phase II clinical trials for focal cortical dysplasia
  • Targets the molecular pathway (mTOR) that is overactive due to genetic mutations in brain tissue
  • Aims to address the underlying cellular abnormality rather than just managing symptoms
  • Based on discoveries of brain-only mutations in TSC1, TSC2, and MTOR genes in patients
  • Represents a precision medicine approach to epilepsy treatment